Pramlintide-metreleptin combination therapy

Drug Profile

Pramlintide-metreleptin combination therapy

Alternative Names: AC 137-164594

Latest Information Update: 24 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Adipokines; Anorectics; Proteins
  • Mechanism of Action Adipokine receptor agonists; Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 25 Dec 2012 Amylin Pharmaceuticals and Takeda terminate their agreement for this programme
  • 04 Aug 2011 Discontinued - Phase-II for Obesity in USA (SC)
  • 17 Mar 2011 Amylin and Takeda voluntarily suspend clinical activities in a phase II trial (NCT01235741) in Obesity in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top